Approved for use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY PATENT APPLICATION TRANSMITTAL

6. Application Data Sheet. See 37 CFR 1.76

or in an Application Data Sheet under 37 CFR 1.76:

Attorney Docket No. 015389-002640US

First Inventor Cech,Thomas

Title HUMAN TELOMERASE CATALYTIC SUBUNIT: DIAGNOSTIC AND THERAPEUTIC METHODS

Other: Communication Under 37 CFR § 1.821(e)

Fax

Date

Registration No. (Attorney/Agent)

47,163

January 11, 2002

Express Mail Label No. EL670763235US (Only for new nonprovisional applications under 37 C.F.R. § 1.53(b)) Assistant Commissioner for Patents APPLICATION ELEMENTS ADDRESS TO Box Patent Application Washington, DC 20231 See MPEP chapter 600 concerning design patent application contents. 7. CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (e.g., PTO/SB/17) 1. 🛛 Computer Program (Appendix) (Submit an original and a duplicate for fee processing) 8. Nucleotide and/or Amino Acid Sequence Submission 2. Applicant claims small entity status. (if applicable, all necessary) See 37 CFR 1.27. a. Computer Readable Form (CRF) [Total Pages 191 з. 🖂 Specification b. Specification Sequence Listing on: (preferred arrangement set forth below) - Descriptive title of the Invention i. CD-ROM or CD-R (2 copies); or - Cross References to Related Applications paper number of pages 177 - Statement Regarding Fed sponsored R & D c. 

Statements verifying identity of above copies - Reference to sequence listing, a table, or a computer program listing appendix

- Background of the Invention **ACCOMPANYING APPLICATIONS PARTS** Assignment Papers (cover sheet & document(s)) - Brief Summary of the Invention 9. - Brief Description of the Drawings ( if filed) 37 C.F.R.§3.73(b)Statement Power of 10. 🔲 - Detailed Description Attorney (when there is an assignee) - Claim(s) - Abstract of the Disclosure English Translation Document (if applicable) 11. Copies of IDS 12. 🛛 Information Disclosure 4. 🛛 Drawing(s) (35 U.S.C.113) [Total Sheets 34 1 Statement (IDS)/PTO-1449 Citations [Total Pages | 8 1 5. Oath or Declaration 13. Preliminary Amendment Newly executed (original or copy) Return Receipt Postcard (MPEP 503) 14. 🛛 b. Copy from a prior application (37 CFR 1.63 (d)) (Should be specifically itemized) (for a continuation/divisional with Box 18 completed) Certified Copy of Priority Document(s) 15. 🔲 i. DELETION OF INVENTOR(S) (if foreign priority is claimed) Signed statement attached deleting inventor(s) Nonpublication Request under 35 U.S.C. 16. named in the prior application, see 37 CFR 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 1.63(d)(2) and 1.33(b). or its equivalent

	uation 🔲 Divisional	☐ Continuation-in-part (CIP)	of prior application No. <u>08</u> / <u>912,951</u>						
Prior appl		Examiner <u>J. Andres, Ph D.</u>	Group Art Unit: <u>1646</u>						
under Boy 5h	s ie concidared a nart of th	e disclosure of the accompanying confi	or application, from which an oath or declaration is su nuation or divisional application and is hereby incorpo nadvertently omitted from the submitted application p	orated by					
19. CORRESPONDENCE ADDRESS									
☑ Custome	er Number or Bar Code Labe	el 20350 (Insert Customer No. or Attach bar c	or ☐ Correspondence address b ode label here)	pelow					
Name -									
Address	44								
City		State	Zip Code						

17. 🛛

18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231. PA 3194860 v1

Telephone

**Hugh Wang** 

The state of the s

Country

Signature

Name (Print/Type)

2

T

## ATTHE AND AND ATTHE ATTH 43 翻號 ļ

FEE	TR	AN	SM	ĮΤΊ	TAL
•	for	FY	200	)1	

Patent fees are subject to annual revision

	Complete if Known	
Application Number	Not yet assigned	
Filing Date	January 11, 2002	
First Named Inventor	Thomas Cech	
Examiner Name	Not yet assigned	
Group Art Unit	Not yet assigned	
Attorney Docket No.	015389-002640US	

TOTAL AMOUNT OF PAYMENT (\$) 740		Attorne	y Docke	t No.	01538	9-002640US	/
METHOD OF PAYMENT					FEE CA	ALCULATION (continued)	
The Commissioner is hereby authorized to c indicated fees and credit any over payments		3. ADDI Large Fee	TIONAL Entity Fee		Entity Fee		Fee
Deposit 00 4420		Code	(\$)	Code	(\$)	Fee Description	Paid
Account 20-1430		105	130	205	65	Surcharge - late filing fee or oath	
Deposit	127	50	227	25	Surcharge - late provisional filing fee or cover sheet		
Account Townsend and Townsend and Crew LLP		139	130	139	130	Non-English specification	
Name		147	2,520	147	2,520	For filing a request for reexamination	
		112	920*	112	920*	Requesting publication of SIR prior to Examiner action	
Applicant claims small entity status.  See 37 CFR 1.27		113	1,840*	113	1,840*	Requesting publication of SIR after Examiner action	
2. Payment Enclosed:		115	110	215	55	Extension for reply within first month	
☐ Check ☐ Credit card ☐ Money ☐ Other	er	116	400	216	200	Extension for reply within second month	
Order		117	920	217	460	Extension for reply within third month	
1. BASIC FILING FEE		118	1,440	218	720	Extension for reply within fourth month	
Large Entity Small Entity		128	1,960	228	980	Extension for reply within fifth month	
Fee Fee Fee Fee Description		119	320	219	160	Notice of Appeal	
	ee Paid	120	320	220	160	Filing a brief in support of an appeal	
101 740 201 370 Utility filing fee 7	40	121	280	221	140	Request for oral hearing	
106 330 206 165 Design filing fee 107 510 207 255 Plant filing fee		138	1,510	138	1,510	Petition to institute a public use proceeding	
108 740 208 370 Reissue filing fee		140	110	240	55	Petition to revive – unavoidable	
114 160 214 80 Provisional filing fee		141	1,280	241	640	Petition to revive – unintentional	
		142	1,280	242	640	Utility issue fee (or reissue)	
SUBTOTAL (1)	\$)740	143	460	243	230	Design issue fee	
2. EXTRA CLAIM FEES		144	620	244	310	Plant issue fee	
Extra Fee from	Fee	122	130	122	130	Petitions to the Commissioner	
Claims below  Total Claims 20 -20** = 0 X \$18 =	Paid \$0	123	50	123	50	Petitions related to provisional applications	
ndependent 1 -3** = 0 X \$84 =	\$0	126	180	126	180	Submission of Information Disclosure Stmt	
Multiple X = [		581	40	581	40	Recording each patent assignment per property (times number of properties)	
Large Entity Small Entity Fee Fee Fee Fee Fee Fee Fee Fee Fee		146	740	246	370	Filing a submission after final rejection (37 CFR § 1.129(a))	
Code (\$) Code (\$)  103 18 203 9 Claims in excess of 20		149	740	249	370	For each additional invention to be examined (37 CFR § 1.129(b))	
102 84 202 42 Independent claims in exce	ess of 3	179	740	279	370	Request for Continued Examination (RCE)	
104 280 204 140 Multiple dependent claim, i						Y'	
109 84 209 42 ** Reissue independent cla original patent	aims over	169	900	169	900	Request for expedited examination of a design application	
110 18 210 9 *** Reissue claims in exces over original patent	ss of 20 and	Other fee (specify)					
SUBTOTAL (2) (\$)0		The Commissioner is authorized to charge any additional fees to the above noted Deposit Account.					
**or number previously hald if greater For Reissues see above		*Reduc	ed by Ba	sic Filin	g Fee Pa	aid SUBTOTAL (3) (\$)	

SUBMITTED BY						
Name (Print/Type)	Hugh Wang	Registration No (Attorney/Agent)	47,163	Telephone	650-326-2400	
Signature		Alter		Date	January 11, 2002	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Attorney Docket No.: 015389-002640US Client Ref. No.: 018/213C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Thomas R. Cech et al.

Application No.: Unassigned

Filed: Herewith

For: Human Telomerase Catalytic Subunit: Diagnostic and Therapeutic

Methods

Examiner:

Unassigned

Art Unit:

Unassigned

COMMUNICATION UNDER

37 C.F.R. § 1.821(e)

**Assistant Commissioner for Patents** Washington, D.C. 20231

Sir:

In order to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, Applicants submit herewith the required paper copy of the Sequence Listing. Applicants request use of the acceptable computer-readable form filed in the parent Application No. 08/912,951 (filed August 14, 1997; Attorney Docket No.: 015389-002600US) as the computerreadable form for the instant application, pursuant to 37 C.F.R. § 1.821(e). It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Pursuant to 37 C.F.R. 1.821(e), Applicants attest that the paper copy of the Sequence Listing filed herewith is identical to the paper copy and computer readable copy of the sequence listing submitted in the parent Application No. 08/912,951, and introduces no new matter.

Cech et al.

Application No.: Unassigned

Page +

If the Examiner believes a telephone conference would expedite prosecution of this application, please telephone the undersigned at 650-326-2400 x 5209.

Respectfully submitted,

Hugh Wang Reg. No. 47,163

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8<sup>th</sup> Floor San Francisco, California 94111-3834 Tel: (650) 326-2400 Fax: (415) 576-0300

PA 3194171 v1